Advertisement

Rheumatology International

, Volume 39, Issue 7, pp 1201–1212 | Cite as

Intravenous human immunoglobulin and/or methylprednisolone pulse therapies as a possible treat-to-target strategy in immune-mediated necrotizing myopathies

  • Jean Marcos de SouzaEmail author
  • Leonardo Santos Hoff
  • Samuel Katsuyuki Shinjo
Observational Research
  • 160 Downloads

Abstract

To evaluate the relevance of immunoglobulin (IVIg) and/or methylprednisolone pulse therapies in immune-mediated necrotizing myopathy (IMNM). Secondarily, to analyze the muscle damage measured by late magnetic resonance images (MRI). This retrospective study included 13 patients with defined IMNM (nine patients positive for the anti-signal recognition particle and four patients positive for hydroxyl-methyl-glutaryl coenzyme A reductase) who were followed from 2012 to 2018. International Myositis Assessment and Clinical Studies Group (IMACS) scoring assessed the response to a standardized treat-to-target protocol with disease activity core-set measures and late magnetic resonance imaging (MRI). The patients had a mean age of 53.5 years and were predominantly female and of white ethnicity. Median symptom and mean follow-up durations were 4 and 39 months, respectively. All patients received IVIg and/or methylprednisolone pulse therapies. All IMACS core-set measurements improved significantly after initial treatment. Nine patients achieved complete clinical response and among them 2 had complete remission. Eleven patients had discontinued glucocorticoid use by the end of the study. Only 2 patients had moderate muscle atrophy or fat replacement observed by MRI, with the remainder presenting normal or mild findings. Our patients with IMNM treated with an aggressive immunosuppressant therapy had a marked improvement in all IMACS core-set domains. Moreover, the MRI findings suggest that an early treat-to-target approach could reduce the odds of long-term muscle disability. Methylprednisolone and/or IVIg pulse therapies aiming at a target of complete clinical response are potential treatment strategies for IMNM that should be studied in future prospective studies.

Keywords

Glucocorticoids Intravenous human immunoglobulin Magnetic resonance Methylprednisolone Necrotizing myopathies 

Notes

Funding

This work was funded by: Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) #2017/13109-1 and Faculdade de Medicina da Universidade de São Paulo to S.K.S.

Compliance with ethical standards

Conflict of interest

Jean Marcos de Souza, Leonardo Santos Hoff and Samuel Katsuyuki Shinjo declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Dalakas MC (2015) Inflammatory muscle diseases. N Engl J Med 372:1734–1747CrossRefGoogle Scholar
  2. 2.
    Dalakas MC (2011) Review: an update on inflammatory and autoimmune myopathies. Neuropathol Appl Neurobiol 37:226–242CrossRefGoogle Scholar
  3. 3.
    Basharat P, Christopher-Stine L (2015) Immune-mediated necrotizing myopathy: update on diagnosis and management. Curr Rheumatol Rep 17:72CrossRefGoogle Scholar
  4. 4.
    Bronner IM, Hoogendijk JE, Wintzen AR, van der Meulen MF, Linssen WH, Wokke JH, de Visser M (2003) Necrotising myopathy, an unusual presentation of a steroid-responsive myopathy. J Neurol 250:480–485CrossRefGoogle Scholar
  5. 5.
    Carroll MB, Newkirk MR, Sumner NS (2016) Necrotizing autoimmune myopathy: a unique subset of idiopathic inflammatory myopathy. J Clin Rheumatol 22:376–380CrossRefGoogle Scholar
  6. 6.
    Mammen AL, Pak K, Williams EK, Brisson D, Coresh J, Selvin E, Gaudet (2012) Rarity of anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies in statin users, including those with self-limited musculoskeletal side effects. Arthritis Care Res 64:269–272CrossRefGoogle Scholar
  7. 7.
    Mammen AL, Tiniakou E (2015) Intravenous immune globulin for statin-triggered autoimmune myopathy. N Engl J Med 373:1680–1682CrossRefGoogle Scholar
  8. 8.
    Hengstman GJ, ter Laak HJ, Vree Egberts WT, Lundberg IE, Moutsopoulos HM, Vencovsky J, Doria A, Mosca M, van Venrooij WJ, van Engelen BG (2006) Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy. Ann Rheum Dis 65:1635–1638CrossRefGoogle Scholar
  9. 9.
    Kao AH, Lacomis D, Lucas M, Fertig N, Oddis CV (2004) Anti-signal recognition particle autoantibody in patients with and patients without idiopathic inflammatory myopathy. Arthritis Rheum 50:209–215CrossRefGoogle Scholar
  10. 10.
    Grable-Esposito P, Katzberg HD, Greenberg SA, Srinivasan J, Katz J, Amato AA (2010) Immune-mediated necrotizing myopathy associated with statins. Muscle Nerve 41:185–190Google Scholar
  11. 11.
    Pinal-Fernandez I, Casal-Dominguez M, Carrino JA, Lahouti AH, Basharat P, Albayda J, Paik JJ, Ahlawat S, Danoff SK, Lloyd TE, Mammen AL, Christopher-Stine L (2017) Thigh muscle MRI in immune-mediated necrotising myopathy: extensive oedema, early muscle damage and role of anti-SRP autoantibodies as a marker of severity. Ann Rheum Dis 76:681–687CrossRefGoogle Scholar
  12. 12.
    Zheng Y, Liu L, Wang L, Xiao J, Wang Z, Lv H, Zhang W, Yuan Y (2015) Magnetic resonance imaging changes of thigh muscles in myopathy with antibodies to signal recognition particle. Rheumatology 54:1017–1024CrossRefGoogle Scholar
  13. 13.
    Christopher-Stine L, Casciola-Rosen LA, Hong G, Chung T, Corse AM, Mammen AL (2010) A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy. Arthritis Rheum 62:2757–2766CrossRefGoogle Scholar
  14. 14.
    Mammen AL, Pak K, Williams EK, Brisson D, Coresh J, Selvin E, Gaudet D (2012) Rarity of anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies in statin users, including those with self-limited musculoskeletal side effects. Arthritis Care Res (Hoboken) 64:269–272CrossRefGoogle Scholar
  15. 15.
    Miller T, Al-Lozi MT, Lopate G, Pestronk A (2002) Myopathy with antibodies to the signal recognition particle: clinical and pathological features. J Neurol Neurosurg Psychiatry 73:420–428CrossRefGoogle Scholar
  16. 16.
    Suzuki S, Nishikawa A, Kuwana M, Nishimura H, Watanabe Y, Nakahara J, Hayashi YK, Suzuki N, Nishino I (2015) Inflammatory myopathy with anti-signal recognition particle antibodies: case series of 100 patients. Orphanet J Rare Dis 10:61CrossRefGoogle Scholar
  17. 17.
    De Souza FHC, Miossi R, Shinjo SK (2017) Necrotising myopathy associated with anti-signal recognition particle (anti-SRP) antibody. Clin Exp Rheumatol 35:766–771Google Scholar
  18. 18.
    Lundberg IE, Tjärnlund A, Bottai M et al (2017) 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis 76:1955–1964CrossRefGoogle Scholar
  19. 19.
    Cruellas MG, Viana VS, Levy-Neto M, Souza FHC, Shinjo SK (2013) Myositis-specific and myositis-associated autoantibody profiles and their clinical associations in a large series of patients with polymyositis and dermatomyositis. Clinics 68:909–914CrossRefGoogle Scholar
  20. 20.
    Rider LG, Koziol D, Giannini EH, Jain MS, Smith MR, Whitney-Mahoney K, Feldman BM, Wright SJ, Lindsley CB, Pachman LM, Villalba ML, Lovell DJ, Bowyer SL, Plotz PH, Miller FW, Hicks JE (2010) Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies. Arthritis Care Res (Hoboken) 62:465–472CrossRefGoogle Scholar
  21. 21.
    Bruce B, Fries JF (2003) The Stanford Health Assessment Questionnaire: a review of its history, issues, progress, and documentation. J Rheumatol 30:167–178Google Scholar
  22. 22.
    Fries JF, Spitz PW, Young DY (1982) The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales. J Rheumatol 9:789–793Google Scholar
  23. 23.
    Isenberg DA, Allen E, Farewell V, Ehrenstein MR, Hanna MG, Lundberg IE, Oddis C, Pilkington C, Plotz P, Scott D, Vencovsky J, Cooper R, Rider L, Miller F, International Myositis and Clinical Studies Group (IMACS) (2004) International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology 43:49–54CrossRefGoogle Scholar
  24. 24.
    Oddis CV, Rider LG, Reed AM, Ruperto N, Brunner HI, Koneru B, Feldman BM, Giannini EH, Miller FW, International Myositis Assessment and Clinical Studies Group (2005) International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies. Arthritis Rheum 52:2607–2615CrossRefGoogle Scholar
  25. 25.
    Aggarwal R, Rider LG, Ruperto N et al (2017) 2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Ann Rheum Dis 76:792–801CrossRefGoogle Scholar
  26. 26.
    Pestronk A (2011) Acquired immune and inflammatory myopathies: pathologic classification. Curr Opin Rheumatol 23:595–604CrossRefGoogle Scholar
  27. 27.
    Preuβe C, Goebel HH, Held J, Wengert O, Scheibe F, Irlbacher K, Koch A, Heppner FL, Stenzel W (2012) Immune-mediated necrotizing myopathy is characterized by a specific Th1-M1 polarized immune profile. Am J Pathol 181:2161–2171CrossRefGoogle Scholar
  28. 28.
    Basta M, Kirshbom P, Frank MM, Fries LF (1989) Mechanism of therapeutic effect of high-dose intravenous immunoglobulin. Attenuation of acute, complement-dependent immune damage in a guinea pig model. J Clin Invest 84:1974–1981CrossRefGoogle Scholar
  29. 29.
    Dalakas MC, Illa I, Dambrosia JM, Soueidan SA, Stein DP, Otero C, Dinsmore ST, Mccrosky S (1993) A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 329:1993–2000CrossRefGoogle Scholar
  30. 30.
    Ballow M (1991) Mechanisms of action of intravenous immunoglobulin therapy and potential use in autoimmune connective tissue diseases. Cancer 68:1430–1436CrossRefGoogle Scholar
  31. 31.
    Dwyer JM (1992) Manipulating the immune system with immune globulin. N Engl J Med 326:107–116CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Division of Rheumatology, Faculdade de Medicina FMUSPUniversidade de Sao PauloSao PauloBrazil

Personalised recommendations